F&P Healthcare (FPH): Vapotherm Q3 Result − Negative Read-Through
Vapotherm (VAPO.NYSE), a small, pureplay competitor to FPH’s nasal high flow optiflow product has reported its Q3 result this morning; Overall read...
99 Views
F&P Healthcare: Breathing Rate Slows
F&P Healthcare's 1H23 guidance confirmed our prior view of material earnings risks, however, the magnitude was significantly greater than expected
144 Views
F&P Healthcare (FPH): 1H23 Guidance and Trading Update
F&P Healthcare (FPH) has this morning provided an ugly 1H23 guidance update for NPAT of NZ$90m at the mid-point
193 Views
F&P Healthcare: Checking the Flow — June Revenue Proxy
F&P HealthcareChecking the Flow — June Revenue Proxy UNDERPERFORM Our latest proprietary revenue proxy data continues to highlight ongoing...
715 Views
F&P Healthcare: 2022 Investor Day — Checking the Flow
F&P Healthcare2022 Investor Day — Checking the Flow UNDERPERFORM F&P Healthcare's (FPH) 2022 investor day had minimal near-term direct...
706 Views